Pricing Log in Create free account

Agios Pharmaceuticals, Inc. (AGIO) vs Zymeworks Inc. (ZYME)

Agios Pharmaceuticals, Inc. and Zymeworks Inc. are both Biotechnology companies. Agios Pharmaceuticals, Inc. and Zymeworks Inc. are of similar size ($1.9B and $1.8B). Agios Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 140.6% against −69.8%. Zymeworks Inc. has the higher net margin (−404.0% vs −418.2%) and the higher return on invested capital (0.00% vs −70.2%). Across the 17 metrics below, Agios Pharmaceuticals, Inc. leads on 9 and Zymeworks Inc. on 8.

Valuation

Metric AGIO ZYME Biotechnology median
P/E n/m n/m 8.50
P/S 18.95 49.29 9.71
P/B 1.82 22.77 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 12.67 42.01 9.21
Earnings yield (22.38%) (8.06%) (33.15%)
Free cash flow yield (19.60%) (6.63%) (25.50%)

Profitability

Metric AGIO ZYME Biotechnology median
Gross margin 91.99% (246.66%) 65.16%
Operating margin (466.78%) (418.99%) 0.00%
Net margin (418.24%) (404.00%) 0.00%
Free cash flow margin (371.43%) (324.68%) 0.00%
Return on equity (34.34%) (72.31%) (56.36%)
Return on assets (31.89%) (37.25%) (48.04%)
Return on invested capital (70.24%) 0.00% 0.00%

Growth

Metric AGIO ZYME Biotechnology median
Revenue growth (TTM) 140.58% (69.78%) 6.02%
EPS growth (last fiscal year) (161.17%) 33.33% 30.26%
Revenue growth, 5-year CAGR (14.45%) 22.16% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AGIO ZYME Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.22 6.32 4.72
Net debt to EBITDA 1.80 2.81 0.96

Dividend

Metric AGIO ZYME Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AGIO ZYME Biotechnology median
Market cap 1.93b 1.84b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack